Peripheral Artery Disease Medical Services in China

Peripheral artery disease (PAD) is a progressive circulatory condition characterized by atherosclerotic narrowing or blockage of non-coronary arteries—most commonly the femoral, iliac, or popliteal vessels—leading to reduced blood flow to the limbs. Symptoms range from intermittent claudication and rest pain to critical limb ischemia, ulceration, and increased risk of amputation or cardiovascular events. Diagnosis relies on clinical assessment, ankle-brachial index (ABI), duplex ultrasonography, CT angiography, or digital subtraction angiography. Management encompasses lifestyle modification, pharmacotherapy (antiplatelets, statins, antihypertensives), endovascular interventions—including drug-coated balloons, atherectomy, and stenting—and, in advanced cases, surgical bypass. Early intervention significantly improves limb salvage rates and long-term survival.

China offers distinct advantages for PAD treatment: its cardiovascular centers house internationally trained interventional cardiologists and vascular surgeons with extensive experience in complex lower-extremity revascularization. Hospitals deploy state-of-the-art imaging systems (e.g., 256-slice CT, intravascular ultrasound, optical coherence tomography) and next-generation devices approved by both NMPA and CE. Clinical outcomes align with global benchmarks—multi-center studies report primary patency rates exceeding 85% at 12 months post–drug-eluting stent placement. Crucially, comprehensive care—including diagnostics, procedure, and follow-up—is typically 40–60% more cost-effective than in the US or Western Europe, without compromising quality or safety standards.

As a dedicated medical tourism agency, we facilitate seamless access to these high-value services: vetting JCI-accredited hospitals, coordinating appointments with PAD specialists, providing itemized, transparent pricing, and delivering end-to-end support—from visa assistance and travel logistics to post-procedure rehabilitation guidance and multilingual care coordination.

Treatment Options & Itemized Cost Breakdown: Peripheral Artery Disease (PAD)

Non-Surgical / Conservative Management

*Target criteria:* Claudication without rest pain, ABI ≥0.4, no tissue loss, stable comorbidities (e.g., controlled hypertension, diabetes).

• •Lifestyle & Supervised Exercise Therapy

- Smoking cessation counseling + pharmacotherapy (varenicline 12-week course): $65–$95

• •Pharmacotherapy (3-month starter regimen)

- High-intensity statin (atorvastatin 40–80 mg/day): $12–$20 - Antihypertensive (amlodipine or ACEi, generic): $8–$15 - Cilostazol (100 mg BID, if no heart failure): $110–$165

• •Diagnostic Monitoring (per episode)

- Fasting lipid panel + HbA1c + renal function (Cr, eGFR): $35–$50 - Duplex ultrasound (full lower limb mapping): $120–$180

Surgical / Interventional Procedures

*Eligibility:* Rest pain, non-healing ulcer (Rutherford Class 4–5), critical limb ischemia (CLI), failed conservative therapy, anatomically suitable lesions.

• •Endovascular Revascularization

- Drug-coated balloon (DCB) angioplasty (≥2 lesions or in-stent restenosis): $3,800–$5,600 - Bare-metal stent (femoropopliteal): $2,900–$4,300 - Nitinol self-expanding stent (below-knee): $4,500–$6,700

• •Open Surgical Bypass

- Femoral-tibial bypass (vein graft, complex CLI): $7,800–$11,200

• •Preoperative Workup (mandatory for all procedures)

- Cardiac stress test (if CAD suspected) + ECG + echocardiogram: $320–$480 - Coagulation panel + crossmatch + infection screen: $95–$140

Special/Complex Condition Management

• •Chronic Limb-Threatening Ischemia (CLTI) with Diabetes & Renal Failure

- Wound care coordination (multidisciplinary clinic, 4-week intensive): $1,100–$1,700

• •In-Stent Restenosis or Graft Failure

Quick Selection Guide

• •Age <65, mild claudication, budget <$500: Start with supervised exercise + dual antiplatelet/statin ($350–$500 total)
• •Age 65–80, Rutherford Class 3–4, moderate budget ($3,000–$6,000): DCB angioplasty ($3,800–$5,600) — optimal balance of efficacy and durability
• •Age >80, CLI + diabetes + renal impairment, urgent limb salvage: Vein bypass ($7,800–$11,200) — superior long-term patency vs. stents in below-knee disease
• •Severe comorbidities (NYHA III–IV HF, eGFR <30): Palliative medical management only — avoid invasive procedures; focus on pain control and wound prevention ($200–$400/month)